|Mr. Jeffrey N. Simmons||Pres, CEO & Director||1.73M||N/A||1967|
|Mr. Todd S. Young||Exec. VP & CFO||379.52k||N/A||1972|
|Mr. David S. Kinard||Exec. VP of HR||626.41k||N/A||1967|
|Ms. Sarena S. Lin||Exec. VP of Elanco USA, Corp. Strategy & Global Marketing||1.52M||N/A||1971|
|Mr. David Alan Urbanek||Exec. VP of Manufacturing & Quality||637.88k||N/A||1966|
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production. It sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated has a research and development collaboration with AgBiome, Inc. to develop nutritional health products for swine. The company was founded in 1954 and is headquartered in Greenfield, Indiana. Elanco Animal Health Incorporated is a subsidiary of Eli Lilly and Company.
Elanco Animal Health Incorporated’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 3.